The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria

Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology

(2011) Shahrokh F. Shariat et al.   CANCER

Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis

(2010) Mario W. Kramer et al.   CANCER

Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy

(2009) Dinesh K. Ahirwar et al.   BIOMARKERS

Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection

(2009) Yair Lotan et al.   BJU INTERNATIONAL

IS IT TIME TO RE-DESIGN THE HAEMATURIA CLINIC?

(2009) Hugh Mostafid et al.   BJU INTERNATIONAL

Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker

(2009) Yair Lotan et al.   JOURNAL OF UROLOGY

Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease

(2009) Bruce A. Julian et al.   Proteomics Clinical Applications

Genetic Association of Monocyte Chemoattractant Protein 1 (MCP-1)-2518 Polymorphism in Mexican Patients With Transitional Cell Carcinoma of the Bladder

(2009) Luis Gabriel Vázquez-Lavista et al.   UROLOGY

Hyaluronic Acid Synthase-1 Expression Regulates Bladder Cancer Growth, Invasion, and Angiogenesis through CD44

(2008) R. Golshani et al.   CANCER RESEARCH

Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase Species

(2008) R. Roy et al.   CLINICAL CANCER RESEARCH